Overcoming implementation challenges of personalized cancer therapy (Q38031117)

27 August 2017

title

Overcoming implementation challenges of personalized cancer therapy (English)

1 reference

27 August 2017

1

Funda Meric-Bernstam

1 reference

27 August 2017

2

Gordon B Mills

1 reference

27 August 2017

language of work or name

English

0 references

publication date

31 July 2012

1 reference

Nature Reviews Clinical Oncology

27 August 2017

published in

1 reference

27 August 2017

volume

9

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

542-548

1 reference

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Cancer stem cells: an old idea--a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Clonal Origin of Human Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Evidence for common clonal origin of multifocal lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Tumour evolution inferred by single-cell sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Whole cancer genome sequencing by next-generation methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Detection and quantification of mutations in the plasma of patients with colorectal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

An emerging toolkit for targeted cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Utilizing RNA interference to enhance cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Trends in the use and role of biomarkers in phase I oncology trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Effective incorporation of biomarkers into phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

21 January 2018

Ethics of n-of-1 trials

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Randomised study of n of 1 trials versus standard practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

The ethical use of mandatory research biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Profiling critical cancer gene mutations in clinical tumor samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Computational methods for discovering structural variation with next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Future of personalized medicine in oncology: a systems biology approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Confronting real time ethical, legal, and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Social networkers' attitudes toward direct-to-consumer personal genome testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Monoclonal Origin of Multicentric Kaposi's Sarcoma Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Targeting the missing links for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Biomarkers in early clinical trials: the committed and the skeptics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

The search for more clinically meaningful research designs: single-patient randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.127

Expression profile of tyrosine kinases in breast cancer.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22850751

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2012.127

1 reference

27 August 2017

1 reference